The Study of Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
One of the main points in the biological trends is, the circadian rhythm and disturbance in this cycle, which cause mood disorders and irregularity in this bio clock, to get depression. The pineal gland with the precise regulation of circadian rhythm of melatonin regulates the brain haemostasis. The abnormal function of this gland gives rise to psychiatric disorders.
In the period of youth and early of middle-age cause biochemical changes and disturbance in biorhythm including melatonin secretion.
This process can change the peak of melatonin phase. In addition, a decrease in the level of serum melatonin, can change the function of immune system of depressed patients. This function facilitates the process of cancerous cell formation and tumor growth.
With respect to the conflicting results and that the positive and negative roles of melatonin in the creation of depression is unknown, the aim of this study was to compare the morning and nocturnal serum melatonin rhythm levels in the patients with Major Depressive Disorder. The second purpose was to measure the morning and nocturnal serum melatonin levels in the depressed and healthy men and women.
| Condition |
|---|
|
Major Depressive Disorder |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Retrospective |
| Official Title: | The Study of Morning and Nocturnal Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder |
- Depression status(measured by Beck depression inventory (BDII-II)) [ Time Frame: 2weeks ] [ Designated as safety issue: No ]
- Measurements of morning and nocturnal melatonin levels by ELISA kit (cat no. RE54021) from the IBL-Hamburg. [ Time Frame: 1 week ] [ Designated as safety issue: No ]The blood vein (5 milliliters) was taken from two groups at 8:00 am on a particular day. At the end of the same day and 24:00 h, the subjects were retaken the blood samples under the dim light.
| Estimated Enrollment: | 92 |
| Study Start Date: | August 2010 |
| Study Completion Date: | October 2010 |
| Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Major Depression Disorder
This study is analytical cross-sectional and randomized. Two groups of depressed patients and healthy subjects were selected.The individual were submitted to a medical examination, and responded to the Beck depression inventory (BDII-II). Those, who got a score above 20, were included in the depressed group. Among this group, 50 patients were chosen randomly. those who obtained a depressive score below 9, 50 of them were chosen and they were included in the healthy group. The control group was chosen to match to the depressed patients for education, social occasion, occupational and economical situation. All of the subjects were interviewed psychiatrically, and the depression disorder was confirmed on the basis of the DSM criteria. eight out of 50 depressed patients were excluded from the study due to suffering from other psychiatric disorders .
|
Eligibility| Ages Eligible for Study: | 22 Years to 48 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
The individuals were chosen who referred to the industrial medical unit of one of big company.
Inclusion Criteria:
- age: 22-48 years old
- gender: male, female
- who got a depressive score above 20, were included in the depressed group
- those who obtained a depressive score below 9, were chosen and they were included in the healthy control group.
- the healthy control group to match to the depressed patients for education, social occasion, occupational and economical situation.
- the depression disorder was confirmed on the basis of the DSM criteria
Exclusion Criteria:
- present or past psychiatric
- physical diagnoses
- drug consumption
- use of narcotic substances
- physical and psychosomatic disorders
- the stressor
- malfunction of thyroid gland
- shift working
Contacts and Locations| Iran, Islamic Republic of | |
| Shahnaz Khaleghipour | |
| Isfahan, Iran, Islamic Republic of, 81989 | |
| Principal Investigator: | Shahnaz Khaleghipour, PhD | Science and Research Branch Islamic Azad University Khozestan |
More Information
No publications provided by Science & Research Islamic Azad University Branch Khozestan
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | shahnaz Khaleghipour, Science & Research Islamic Azad University Branch Khozestan |
| ClinicalTrials.gov Identifier: | NCT01357083 History of Changes |
| Other Study ID Numbers: | 9460, CCT-NAPN-21087 |
| Study First Received: | May 10, 2011 |
| Last Updated: | May 19, 2011 |
| Health Authority: | Iran: Ethics Committee |
Keywords provided by Science & Research Islamic Azad University Branch Khozestan:
|
Melatonin Periodicity Depressive disorder, major Serum Depression |
Additional relevant MeSH terms:
|
Depressive Disorder Depression Depressive Disorder, Major Mood Disorders Mental Disorders Behavioral Symptoms Melatonin Central Nervous System Depressants |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |
ClinicalTrials.gov processed this record on May 16, 2013